{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:50:11Z","timestamp":1793717411922,"version":"4.6.1"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>Cannabidiol (CBD) is a phytocannabinoid without intoxicating properties. While CBD can improve neurophysiological functions and subjective symptoms, its effect on cognitive function remains unclear. We summarized the available randomized controlled trials investigating CBD administration and cognitive function. A review of the literature was conducted using the following keywords on PubMed\/Medline: (cannabis OR cannabidiol OR cannabinoid OR CBD OR \u0394<jats:sup>9<\/jats:sup>-tetrahydrocannabinol OR tetrahydrocannabinol) AND (neurology OR brain OR psychiatric OR neuroscience OR psychology OR cognition) AND (human) AND (randomized controlled trial OR RCT). The search yielded 1038 articles with 36 total included for this literature review. The articles included healthy participants, neurological disease, psychiatric disease, psychosis, paranoia, schizophrenia, and drug-use disorders. Studies with healthy participants included a variety of dosing strategies, suggesting an effect on cognitive function and sleep quality. In Parkinson\u2019s disease, 75\u2013300\u2005mg CBD resulted in mild improvements in daily life activities. Decreases in subjective anxiety were found in patients with psychiatric disease using CBD doses ranging from 300 to 400\u2005mg. In patients with psychosis and paranoia, 600\u2005mg CBD showed inconsistent results in cognitive function. In patients with schizophrenia, up to 1000\u2005mg CBD per day had minimal effects on cognition. Finally, up to 800\u2005mg CBD had minimal effects on cognitive function in patients with substance use disorders. The findings are limited by utilization of acute dosing, variations in CBD dose, and different routes of administration. Standardized dosing and CBD formulations are needed to assess its efficacy for improving cognition.<\/jats:p>","DOI":"10.1097\/fbp.0000000000000837","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T11:00:10Z","timestamp":1749553210000},"page":"203-216","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Cannabidiol and cognition: a literature review of human randomized controlled trials"],"prefix":"10.1097","volume":"36","author":[{"given":"Jyotpal","family":"Singh","sequence":"first","affiliation":[{"name":"Faculty of Kinesiology and Health Studies, University of Regina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chase J.","family":"Ellingson","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Saskatchewan Regina Campus, Regina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Abdullah","family":"Shafiq","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Saskatchewan Regina Campus, Regina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Alcorn","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Patrick","family":"Neary","sequence":"additional","affiliation":[{"name":"Faculty of Kinesiology and Health Studies, University of Regina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"R1-20250703","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/mds.28577","article-title":"Cannabidiol for rapid eye movement sleep behavior disorder.","volume":"36","author":"de Almeida","year":"2021","journal-title":"Mov Disord"},{"key":"R2-20250703","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00213-019-05442-6","article-title":"Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis.","volume":"237","author":"Appiah-Kusi","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"key":"R3-20250703","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/cts.13425","article-title":"The safety and efficacy of low oral doses of cannabidiol: an evaluation of the evidence.","volume":"16","author":"Arnold","year":"2023","journal-title":"Clin Transl Sci"},{"key":"R4-20250703","first-page":"1","article-title":"Antioxidative and anti-inflammatory properties of cannabidiol.","volume":"9","author":"Atalay","year":"2019","journal-title":"Antioxidants (Basel)"},{"key":"R5-20250703","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2023.1087011","article-title":"Cannabidiol\u2019s neuroprotective properties and potential treatment of traumatic brain injuries [Review].","volume":"14","author":"Aychman","year":"2023","journal-title":"Front Neurol"},{"key":"R6-20250703","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drugalcdep.2016.11.030","article-title":"Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers.","volume":"172","author":"Babalonis","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"R7-20250703","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients.","volume":"36","author":"Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"R8-20250703","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/npp.2009.184","article-title":"Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.","volume":"35","author":"Bhattacharyya","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"R9-20250703","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/jamapsychiatry.2018.2309","article-title":"Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis: a randomized clinical trial.","volume":"75","author":"Bhattacharyya","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"R10-20250703","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s00213-022-06070-3","article-title":"The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging study.","volume":"239","author":"Bloomfield","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"R11-20250703","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00213-018-4885-9","article-title":"The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.","volume":"235","author":"Boggs","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"R12-20250703","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1590\/1516-4446-2021-2317","article-title":"The anxiolytic effect of cannabidiol depends on the nature of the trauma when patients with post-traumatic stress disorder recall their trigger event.","volume":"44","author":"Bolsoni","year":"2022","journal-title":"Braz J Psychiatry"},{"key":"R13-20250703","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.biopsych.2008.05.011","article-title":"Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition.","volume":"64","author":"Borgwardt","year":"2008","journal-title":"Biol Psychiatry"},{"key":"R14-20250703","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1177\/0269881114550355","article-title":"Effects of cannabidiol in the treatment of patients with Parkinson\u2019s disease: an exploratory double-blind trial.","volume":"28","author":"Chagas","year":"2014","journal-title":"J Psychopharmacol"},{"key":"R15-20250703","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-G","article-title":"Controlled clinical trial of cannabidiol in Huntington\u2019s disease.","volume":"40","author":"Consroe","year":"1991","journal-title":"Pharmacol Biochem Behav"},{"key":"R16-20250703","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/sj.npp.1300340","article-title":"Effects of cannabidiol (CBD) on regional cerebral blood flow.","volume":"29","author":"Crippa","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"R17-20250703","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1590\/1516-4446-2020-1684","article-title":"Effect of two oral formulations of cannabidiol on responses to emotional stimuli in healthy human volunteers: pharmaceutical vehicle matters.","volume":"44","author":"Crippa","year":"2022","journal-title":"Braz J Psychiatry"},{"key":"R18-20250703","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41398-020-0862-2","article-title":"A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis.","volume":"10","author":"Davies","year":"2020","journal-title":"Transl Psychiatry"},{"key":"R19-20250703","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00406-021-01318-z","article-title":"Altered relationship between cortisol response to social stress and mediotemporal function during fear processing in people at clinical high risk for psychosis: a preliminary report.","volume":"272","author":"Davies","year":"2022","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"R20-20250703","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1089\/acm.2018.0437","article-title":"Cannabidiol in the treatment of post-traumatic stress disorder: a case series.","volume":"25","author":"Elms","year":"2019","journal-title":"J Altern Complement Med"},{"key":"R21-20250703","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/0269881119895536","article-title":"Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson\u2019s disease.","volume":"34","author":"de Faria","year":"2020","journal-title":"J Psychopharmacol"},{"key":"R22-20250703","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2174\/1570159X17666190903103923","article-title":"The \u2018entourage effect\u2019: terpenes coupled with cannabinoids for the treatment of mood disorders and anxiety disorders.","volume":"18","author":"Ferber","year":"2020","journal-title":"Curr Neuropharmacol"},{"key":"R23-20250703","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archgenpsychiatry.2008.519","article-title":"Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing.","volume":"66","author":"Fusar-Poli","year":"2009","journal-title":"Arch Gen Psychiatry"},{"key":"R24-20250703","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1017\/S1461145709990617","article-title":"Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol.","volume":"13","author":"Fusar-Poli","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"R25-20250703","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biom10111575","article-title":"Cannabidiol: a potential new alternative for the treatment of anxiety, depression, and psychotic disorders.","volume":"10","author":"Garcia-Gutierrez","year":"2020","journal-title":"Biomolecules"},{"key":"R26-20250703","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.euroneuro.2018.04.004","article-title":"Probing the endocannabinoid system in healthy volunteers: cannabidiol alters fronto-striatal resting-state connectivity.","volume":"28","author":"Grimm","year":"2018","journal-title":"Eur Neuropsychopharmacol"},{"key":"R27-20250703","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.pnpbp.2010.11.002","article-title":"The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects.","volume":"35","author":"Hallak","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R28-20250703","doi-asserted-by":"crossref","first-page":"8268","DOI":"10.1073\/pnas.95.14.8268","article-title":"Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants.","volume":"95","author":"Hampson","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R29-20250703","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.euroneuro.2014.11.014","article-title":"Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.","volume":"25","author":"Hindocha","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"R30-20250703","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jpsychires.2021.09.007","article-title":"Cannabidiol enhances verbal episodic memory in healthy young participants: a randomized clinical trial.","volume":"143","author":"Hotz","year":"2021","journal-title":"J Psychiatr Res"},{"key":"R31-20250703","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1177\/0269881117737400","article-title":"The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group.","volume":"32","author":"Hundal","year":"2018","journal-title":"J Psychopharmacol"},{"key":"R32-20250703","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1176\/appi.ajp.2019.18101191","article-title":"Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial.","volume":"176","author":"Hurd","year":"2019","journal-title":"Am J Psychiatry"},{"key":"R33-20250703","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.parkreldis.2014.09.014","article-title":"The cognition and emotional well-being indices of the Parkinson\u2019s disease questionnaire-39: what do they really measure?","volume":"20","author":"Jones","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"R34-20250703","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1089\/can.2021.0089","article-title":"Adjunctive management of opioid withdrawal with the nonopioid medication cannabidiol.","volume":"7","author":"Kudrich","year":"2022","journal-title":"Cannabis Cannabinoid Res"},{"key":"R35-20250703","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.euroneuro.2022.04.003","article-title":"Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: a randomised controlled trial.","volume":"59","author":"Kwee","year":"2022","journal-title":"Eur Neuropsychopharmacol"},{"key":"R36-20250703","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor.","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br J Pharmacol"},{"key":"R37-20250703","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1177\/0269881120944148","article-title":"The acute effects of cannabidiol on the neural correlates of reward anticipation and feedback in healthy volunteers.","volume":"34","author":"Lawn","year":"2020","journal-title":"J Psychopharmacol"},{"key":"R38-20250703","doi-asserted-by":"crossref","first-page":"614811","DOI":"10.3389\/fphar.2021.614811","article-title":"Cannabidiol and amisulpride improve cognition in acute schizophrenia in an explorative, double-blind, active-controlled, randomized clinical trial.","volume":"12","author":"Leweke","year":"2021","journal-title":"Front Pharmacol"},{"key":"R39-20250703","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/19390211.2020.1765941","article-title":"Effects of hemp extract on markers of wellness, stress resilience, recovery and clinical biomarkers of safety in overweight, but otherwise healthy subjects.","volume":"17","author":"Lopez","year":"2020","journal-title":"J Diet Suppl"},{"key":"R40-20250703","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.neubiorev.2021.01.003","article-title":"Determining the magnitude and duration of acute \u0394(9)-tetrahydrocannabinol (\u0394(9)-THC)-induced driving and cognitive impairment: a systematic and meta-analytic review.","volume":"126","author":"McCartney","year":"2021","journal-title":"Neurosci Biobehav Rev"},{"key":"R41-20250703","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","article-title":"Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial.","volume":"175","author":"McGuire","year":"2018","journal-title":"Am J Psychiatry"},{"key":"R42-20250703","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3389\/fphar.2018.01365","article-title":"A systematic review on the pharmacokinetics of cannabidiol in humans.","volume":"9","author":"Millar","year":"2018","journal-title":"Front Pharmacol"},{"key":"R43-20250703","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41398-018-0191-x","article-title":"Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function.","volume":"8","author":"Morgan","year":"2018","journal-title":"Transl Psychiatry"},{"key":"R44-20250703","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1248\/bpb.16.428","article-title":"Suppression of liver microsomal drug-metabolizing enzyme activities in adult female rats pretreated with cannabidiol.","volume":"16","author":"Narimatsu","year":"1993","journal-title":"Biol Pharm Bull"},{"key":"R45-20250703","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1017\/S0033291719003519","article-title":"Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis.","volume":"51","author":"O\u2019Neill","year":"2021","journal-title":"Psychol Med"},{"key":"R46-20250703","doi-asserted-by":"crossref","first-page":"595635","DOI":"10.3389\/fphar.2020.595635","article-title":"Cannabidiol as a therapeutic target: evidence of its neuroprotective and neuromodulatory function in Parkinson\u2019s disease.","volume":"11","author":"Patricio","year":"2020","journal-title":"Front Pharmacol"},{"key":"R47-20250703","doi-asserted-by":"crossref","first-page":"173376","DOI":"10.1016\/j.pbb.2022.173376","article-title":"Cannabidiol effects on cognition in individuals with cocaine use disorder: exploratory results from a randomized controlled trial.","volume":"216","author":"Rizkallah","year":"2022","journal-title":"Pharmacol Biochem Behav"},{"key":"R48-20250703","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/j.1476-5381.2011.01238.x","article-title":"Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.","volume":"163","author":"Russo","year":"2011","journal-title":"Br J Pharmacol"},{"key":"R49-20250703","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.yebeh.2018.07.027","article-title":"Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: a randomized, double-blind, controlled trial.","volume":"88","author":"Schoedel","year":"2018","journal-title":"Epilepsy Behav"},{"key":"R50-20250703","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1017\/cjn.2020.23","article-title":"Neuroprotection following concussion: the potential role for cannabidiol.","volume":"47","author":"Singh","year":"2020","journal-title":"Can J Neurol Sci"},{"key":"R51-20250703","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1139\/cjpp-2021-0395","article-title":"Effects of phytocannabinoids on heart rate variability and blood pressure variability in female post-concussion syndrome patients: case series.","volume":"100","author":"Singh","year":"2022","journal-title":"Can J Physiol Pharmacol"},{"key":"R52-20250703","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1089\/can.2017.0043","article-title":"Therapeutic effects of prolonged cannabidiol treatment on psychological symptoms and cognitive function in regular cannabis users: a pragmatic open-label clinical trial.","volume":"3","author":"Solowij","year":"2018","journal-title":"Cannabis Cannabinoid Res"},{"key":"R53-20250703","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics14122598","article-title":"Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020-2022).","volume":"14","author":"Souza","year":"2022","journal-title":"Pharmaceutics"},{"key":"R54-20250703","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3389\/fphar.2017.00081","article-title":"A systematic review and meta-analysis of the haemodynamic effects of cannabidiol.","volume":"8","author":"Sultan","year":"2017","journal-title":"Front Pharmacol"},{"key":"R55-20250703","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","article-title":"A phase i, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects.","volume":"32","author":"Taylor","year":"2018","journal-title":"CNS Drugs"},{"key":"R56-20250703","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41398-019-0534-2","article-title":"Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis.","volume":"9","author":"Wilson","year":"2019","journal-title":"Transl Psychiatry"},{"key":"R57-20250703","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/npp.2011.17","article-title":"Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an FMRI study.","volume":"36","author":"Winton-Brown","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"R58-20250703","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2174\/1389200217666151210142051","article-title":"Cannabinoids and cytochrome P450 interactions.","volume":"17","author":"Zendulka","year":"2016","journal-title":"Curr Drug Metab"}],"container-title":["Behavioural Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000837","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T11:00:34Z","timestamp":1751540434000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/fbp.0000000000000837","relation":{},"ISSN":["0955-8810","1473-5849"],"issn-type":[{"value":"0955-8810","type":"print"},{"value":"1473-5849","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]}}}